natgillin/translations-raw huggingface dataset:
Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting GH therapy.
Intrakranialni tumorji morajo biti neaktivni in protitumorsko zdravljenje končano še pred uvedbo zdravljenja z rastnim hormonom.
• When priming a new cartridge, you may need to repeat Part I, steps 8 and 9 up to a total of
• Med pripravo novega vložka boste morda morali za odstranitev mehurčkov zraka do 6-krat (0,6 mg) ponoviti koraka 8 in 9, opisana v I. delu.
• When your kidneys are damaged and they lose their ability to function normally with an impact on growth.
• če ima otrok okvaro ledvic in ledvice ne delujejo, kar vpliva na rast.
Your doctor should check your thyroid function periodically and if necessary prescribe adequate treatment.
Zdravnik mora redno preverjati delovanje ščitnice in po potrebi uvesti ustrezno zdravljenje.
Bleeding from the womb (uterine haemorrhage) and genital discharge.
Krvavitev iz maternice (uterusa) in izcedek iz spolovila.
Treatment with NutropinAq is a long-term therapy.
Zdravljenje z zdravilom NutropinAq je dolgotrajno.
In addition, patients treated with glucocortocoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses, following initiation of somatropin treatment (see section 4.4).
Pri bolnikih, ki se zaradi predhodno ugotovljenega hipoadrenalizma že zdravijo z glukokortikoidi, bo po uvedbi zdravljenja s somatropinom morda treba povečati vzdrževalni ali stresni odmerek glukokortikoidov (glejte poglavje 4.4).
The shields are optional to help you administer your injection.
Ščitniki so le pomožni pripomoček za injiciranje.
Adults with growth hormone deficiency commonly reported abnormal sensations of tingling, pricking or numbness (paraesthesia), abnormally high levels of blood glucose, excess of lipids (fat) in the blood, sleeplessness, joint disorders, arthrosis (degenerative joint disease), muscle weakness, back pain, breast pain and breast enlargement (gynaecomastia).
Pri odraslih s pomanjkanjem rastnega hormona so pogosto poročali o nenormalnih občutkih v koži, kot zbadanje, ščemenje ali odrevenelost (parestezija), nenormalno visoki vrednosti glukoze v krvi, prekomerni vrednosti lipidov (maščobe) v krvi, nespečnosti, težavah s sklepi, artrozi (degenerativni bolezni sklepov), mišični oslabelosti, bolečinah v hrbtu, bolečinah v prsih in povečanju dojk (ginekomastiji).
Q: How do I replace my NutropinAq Pen?
V: Kako zamenjam injekcijski peresnik NutropinAq Pen?
Adult growth hormone deficient patients treated with somatropin at a mean dosage of 0.014 mg/kg bodyweight daily demonstrate a decrease in fat mass and increase in lean body mass.
Odraslim bolnikom s pomanjkanjem rastnega hormona, zdravljenim s somatropinom v povprečnem dnevnem odmerku 0,014 mg/kg telesne mase, se zmanjša masa maščevja in zveča pusta telesna masa.
Common: Glucose tolerance impaired Uncommon: Hypoglycaemia, hyperphosphatemia
Pogosti: motena toleranca za glukozo Občasni: hipoglikemija, hiperfosfatemija
Low initial doses of 0.15 - 0.3 mg injected each day under the skin (subcutaneous injection).
Majhni začetni odmerek od 0,15 - 0,3 mg, ki se ga vsak dan injicira pod kožo (subkutana injekcija).
Rare: Hypothyroidism
Redki: hipotiroidizem
You should see a drop of solution appear.
Pojaviti se mora kapljica zdravila.
Marketing Authorisation Holder: Ipsen Pharma, 65 quai Georges Gorse, 92100 Boulogne-Billancourt, France
Imetnik dovoljenja za promet z zdravilom: Ipsen Pharma, 65 quai Georges Gorse, 92100 Boulogne-Billancourt, Francija
Linear growth is facilitated in part by growth hormone-stimulated protein synthesis.
Sinteza beljakovin, ki jo stimulira rastni hormon, deloma olajša linearno rast.
- Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation.
- Zdravljenje otrok pred puberteto, ki zaradi kronične insuficience ledvic zaostajajo v rasti, do presaditve ledvice.
How to inject NutropinAq
Kako injicirati zdravilo NutropinAq
Underactivity of the thyroid gland leading to low levels of thyroid hormone (hypothyroidism).
Zmanjšano delovanje ščitnice, ki vodi do nizke ravni ščitničnega hormona (hipotiroidizem).
Somatropin therapy is not indicated in diabetic patients with active proliferative or severe non-proliferative retinopathy.
Pri sladkornih bolnikih z aktivno proliferativno ali s hudo neproliferativno retinopatijo zdravljenje s somatropinom ni indicirano.
Then turn the dose knob clockwise until the first click position is reached (approximately 1/4 turn).
Nato črni odmerni gumb zasučite v smeri urinega kazalca, dokler ne doseže položaja prvega klika (približno
These events are expected in children and were mild/moderate AEs.
Neželeni učinki so bili blagi/zmerni.
Ipsen Pharma, 65 quai Georges Gorse, 92100 Boulogne-Billancourt, France
Ipsen Pharma, 65 quai Georges Gorse, 92100 Boulogne-Billancourt, Francija
Patients with severe hypothyroidism should be treated accordingly prior to the start of NutropinAq therapy.
Bolnike s hudim hipotiroidizmom je treba pred uvedbo zdravila NutropinAq ustrezno zdraviti.
If your cartridge or pen is damaged, ask your doctor or nurse for a replacement.
Če se injekcijski peresnik ali vložek pokvari, se za nadomestnega obrnite na zdravnika ali medicinsko sestro.
Treatment of growth hormone deficient adults with somatropin results in reduced fat mass, increased lean body mass and increased spine bone mineral density.
Zdravljenje odraslih s pomanjkanjem rastnega hormona s somatropinom zmanjša maso maščevja, zveča pusto telesno maso in zveča mineralno gostoto kosti v hrbtenici.
Based on available literature, hypothalamic-pituitary-adrenal axis can be affected and needs to be reassessed during growth hormone therapy in growth hormone deficient patients, who were previously not found to be deficient in this axis.
Na podlagi razpoložljivih podatkov iz literature je delovanje osi hipotalamus-hipofiza-nadledvična žleza lahko prizadeto in ga je pri bolnikih s pomanjkanjem rastnega hormona, pri katerih pomanjkljivo delovanje te osi predhodno ni bilo odkrito, med zdravljenjem z rastnim hormonom treba znova ovrednotiti.
In children with growth hormone deficiency: 0.025 - 0.035 mg/kg bodyweight injected each day under the skin (subcutaneous injection).
Otroci s pomanjkanjem rastnega hormona: 0,025 - 0,035 mg/kg telesne mase, ki se ga vsak dan injicira pod kožo (subkutana injekcija).
Rare: Neoplasm malignant recurrence, melanocytic naevus
Redki: ponovitev malignega tumorja, melanocitni nevus
Available literature data suggest that somatropin clearance is similar in adults and children.
Podatki, ki so na voljo v literaturi, kažejo, da je očistek somatropina pri odraslih in otrocih podoben.
Children with chronic renal insufficiency commonly reported inflammation of the lining of the abdomen (peritonitis), bone necrosis and an increase of creatinine blood levels.
Pri otrocih s kronično insuficienco ledvic so pogosto poročali o vnetju serozne mrene, ki pokriva steno trebušne votline (peritonitis), nekrozi kosti in zvišanju koncentracije kreatinina v krvi.
The most frequently reported adverse reactions from the pivotal and supportive clinical trials were hypothyroidism, impaired glucose tolerance, headache, hypertonia, arthralgia, myalgia, peripheral oedema, oedema, asthenia, injection site reaction and the presence of drug specific antibodies.
V ključnih in podpornih kliničnih preskušanjih so najpogosteje poročali o naslednjih neželenih učinkih: hipotiroidizmu, moteni toleranci za glukozo, glavobolu, hipertoniji, bolečini v sklepih, bolečini v mišicah, perifernem edemu, edemu, asteniji, reakcijah na mestu injiciranja in pojavu specifičnih protiteles proti zdravilu.
• If you undergo a kidney transplant NutropinAq treatment should be stopped.
• Po presaditvi ledvice je treba zdravljenje z zdravilom NutropinAq prekiniti.
Turner syndrome is a genetic abnormality in girls (absence of female sexual chromosome(s)) that prevents growth.
(odsotnost ženskega spolnega kromosoma), kar preprečuje rast.
Rare: Generalised pruritus, urticaria, rash
Redki: generalizirani pruritus, urtikarija, kožni izpuščaj
In girls with Turner syndrome: Up to 0.05 mg/kg bodyweight injected each day under the skin (subcutaneous injection).
Deklice s Turnerjevim sindromom: Do 0,05 mg/kg telesne mase, ki se ga vsak dan injicira pod kožo (subkutana injekcija).
• if you are treated with insulin, your doctor may need to adjust your insulin dose.
• Če se zdravite z insulinom, bo zdravnik morda moral prilagoditi odmerek insulina.
In children, it helps the body to grow and the bones to develop normally.
Pri otrocih zdravilo omogoča normalno rast telesa in razvoj kosti.
Rare: Hypertension
Redki: hipertenzija
Do not remove cartridge between injections.
Vložka med posameznimi injekcijami ne odstranjujte.
Because somatropin may reduce insulin sensitivity, patients should be monitored for evidence of glucose intolerance.
Somatropin lahko zmanjša občutljivost za insulin, zato je bolnike treba nadzorovati glede znakov motene tolerance za glukozo.
Renal transplantation
Presaditev ledvice
After first use, the cartridge may be stored for up to 28 days at 2°C - 8°C.
Po prvi uporabi lahko vložek shranjujete največ 28 dni pri temperaturi 2 °C - 8 °C.
Carbohydrate metabolism
Presnova ogljikovih hidratov
Your doctor or nurse will advise you on the procedure for administering the last dose in the cartridge.
Zdravnik ali medicinska sestra vas bosta seznanila s postopkom za injiciranje zadnjega odmerka v vložku.
As NutropinAq may reduce insulin sensitivity, patients should be monitored for evidence of glucose intolerance.
Zdravilo NutropinAq lahko zmanjša občutljivost za insulin, zato je treba bolnike nadzirati glede znakov motene tolerance za glukozo.
A: Contact your doctor or nurse if you need a replacement part or if you need to replace your entire pen.
O: Če potrebujete nadomestni del ali morate zamenjati celotni injekcijski peresnik, se obrnite na zdravnika ali medicinsko sestro.
65 quai Georges Gorse, 92100 Boulogne-Billancourt, France
65 quai Georges Gorse 92100 Boulogne-Billancourt Francija
Children treated with somatropin have an increased risk of developing pancreatitis compared to adults treated with somatropin.
Zdravljenje s somatropinom je pri otrocih povezano z večjim tveganjem za razvoj vnetja trebušne slinavke kot pri odraslih.
If you forget to take NutropinAq
Če ste pozabili uporabiti zdravilo NutropinAq
In patients with diabetes mellitus requiring drug therapy, the dose of insulin and/or oral hypoglycemic medicinal product may require adjustment when somatropin therapy is initiated (see section 4.4).
Pri bolnikih s sladkorno boleznijo, ki potrebujejo zdravljenje z zdravili, bo po uvedbi zdravljenja s somatropinom morda treba prilagoditi odmerek insulina in/ali peroralnega antidiabetika (glejte poglavje 4.4).
If you are treated with insulin, your doctor may need to adjust your insulin dose.
Če se zdravite z insulinom, bo zdravnik morda moral prilagoditi odmerek insulina.
Other ingredients: sodium chloride, liquefied phenol, polysorbate 20, sodium citrate dihydrate, citric acid anhydrous and water for injections.
Pomožne snovi: natrijev klorid, tekoči fenol, polisorbat 20, natrijev citrat dihidrat, brezvodna citronska kislina in voda za injekcije.
Growth failure associated with chronic renal insufficiency Up to 0.05 mg/kg bodyweight given as a daily subcutaneous injection.
Zaostanek v rasti, povezan s kronično insuficienco ledvic Do 0,05 mg/kg telesne mase v vsakodnevni subkutani injekciji.
Do not remove the cartridge that is being used from the NutropinAq Pen between injections.
Vložka, ki je v uporabi, med injekcijami ne jemljite iz injekcijskega peresnika NutropinAq Pen.
Follow these tips to ensure proper care of your NutropinAq Pen:
del: Shranjevanje in vzdrževanje Upoštevajte ta navodila, da boste pravilno skrbeli za svoj injekcijski peresnik NutropinAq Pen:
Patients with growth hormone failure secondary to CRI should be examined periodically for evidence of progression of renal osteodystrophy.
Pri bolnikih z zaostankom v rasti zaradi kronične ledvične insuficience je treba periodično opravljati preiskave o morebitnem napredovanju ledvične osteodistrofije.
The adverse reactions reported in both adults and children receiving Nutropin, NutropinAq, Nutropin Depot or Protropin (somatrem) are listed in the table below, based on experience from clinical trials all approved indications (642 patients) and post-marketing sources which included a surveillance survey (National Cooperative Growth Study [NCGS] in 35,344 patients).
Podatki o neželenih učinkih izhajajo iz kliničnih preskušanj zdravil pri vseh odobrenih indikacijah (642 bolnikov) in iz spremljanja zdravil v obdobju trženja (National Cooperative Growth Study [študija NCGS]; 35.344 bolnikov).
A new needle should be used for every injection.
O: Da. Za vsako injiciranje uporabite novo iglo.
• Wash your hands thoroughly with soap and water before using your pen.
• Pred uporabo injekcijskega peresnika si dobro umijte roke z milom in vodo.
NutropinAq 10 mg/2 ml (30 IU) solution for injection Somatropin
NutropinAq 10 mg/2 ml (30 i.e.) raztopina za injiciranje somatropin
Very common in adults, common in children: Arthralgia, myalgia Uncommon: Muscle atrophy, bone pain
Zelo pogosti pri odraslih, pogosti pri otrocih: artralgija, mialgija Občasni: mišična atrofija, kostna bolečina
Injection site reactions may be avoided by using the correct injection technique and rotation of injection sites.
Pojav reakcij na mestu injiciranja se lahko prepreči s pravilno tehniko injiciranja in rednim menjavanjem mest injiciranja.
Adults with growth hormone deficiency show low bone mineral density and in the childhood-onset patient, NutropinAq has been shown to increase spine bone mineral density in a dose-dependent manner.
Odrasli s pomanjkanjem rastnega hormona imajo nizko mineralno gostoto kosti in pri bolnikih, ki se jim motnja začne v otroštvu, zdravilo NutropinAq dokazano zveča mineralno gostoto kosti v hrbtenici v odvisnosti od odmerka.
From the 236 patients enrolled into the clinical studies 3 patients had a central nervous system tumour.
O tumorju osrednjega živčevja so poročali pri 3 bolnikih od 236 bolnikov, ki so bili vključeni v klinične študije.
If you have an underactive thyroid gland leading to low levels of thyroid hormone (hypothyroidism) it should be treated before you start NutropinAq treatment.
Pri bolnikih, ki imajo zmanjšano delovanje ščitnice in posledično nizke vrednosti ščitničnega hormona (hipotiroidizem), je treba hipotiroidizem zdraviti pred uvedbo zdravljenja z zdravilom NutropinAq.
The results to Month 60 show continued improvement, and more patients reached height SDS in the normal range.
Rezultati do 60. meseca kažejo kontinuirano izboljšanje.
There was a high incidence of urinary tract infections.
Poročali so tudi o veliki pojavnosti okužbe sečil.
Decrease in muscle size (muscle atrophy), joint pain (arthralgia) and bone pain.
Zmanjšanje velikosti mišic (atrofija mišic), bolečine v sklepih (artralgija) in kostna bolečina.
Of the 139 patients included, 128 completed the first 12 months of therapy, with an average treatment time of 3.2 and 4.6 years and a total exposure of 542 patient years.
Od vključenih 139 bolnikov, je prvih 12 mesecev zdravljenja zaključilo 128 bolnikov.
The other ingredients are sodium chloride, liquefied phenol, polysorbate 20, sodium citrate dihydrate, citric acid anhydrous and water for injections.
- Pomožne snovi so natrijev klorid, tekoči fenol, polisorbat 20, natrijev citrat dihidrat, brezvodna citronskakislina in voda za injekcije.
Growth failure in children due to inadequate growth hormone secretion 0.025 - 0.035 mg/kg bodyweight given as a daily subcutaneous injection.
Zaostanek v rasti otrok zaradi nezadostnega izločanja rastnega hormona 0,025 - 0,035 mg/kg telesne mase v vsakodnevni subkutani injekciji.
Non-clinical data reveal no special hazard for human based on conventional acute and repeated-dose toxicity studies.
Predklinični podatki na osnovi običajnih študij akutne toksičnosti in toksičnosti pri ponavljajočih odmerkih ne kažejo posebnega tveganja za človeka.
Before using your NutropinAq Pen, please read the following instructions carefully.
Pred uporabo injekcijskega peresnika NutropinAq Pen natančno preberite navodilo.
How to use NutropinAq
Kako uporabljati zdravilo NutropinAq
Q: Where should I store my NutropinAq Pen?
V: Kje naj shranjujem injekcijski peresnik NutropinAq Pen?
It is recommended that NutropinAq be administered using sterile, disposable needles.
Zdravilo NutropinAq je priporočljivo aplicirati s sterilnimi injekcijskimi iglami za enkratno uporabo.
Growth rate increased significantly from 3.6-4.1 cm/year at baseline to 6.7-8.1 cm/year at Month 12, 6.7-6.8 cm/year at Month 24 and 4.5-5.1 cm/year at Month 48.
12. mesecu, 6,7-6,8 cm/leto v 24. mesecu in 4,5-5,1 cm/leto v 48. mesecu.
Uncommon: Tachycardia
Občasni: tahikardija
Injection sites include the upper arms, abdomen, and upper thighs.
Mesta injiciranja so lahko nadlakti, trebuh in zgornji del stegen.
However, growth hormone treatment has not been shown to increase the incidence or severity of scoliosis.
Čeprav zdravljenje z rastnim hormonom ni pokazalo zvečanja incidence ali poslabšanja skolioze, je potrebno med zdravljenjem spremljati znake skolioze.
Rare: Abdominal pain, diarrhoea, nausea, vomiting
Redki: abdominalna bolečina, driska, navzea, bruhanje
Clinical efficacy and safety
Klinična učinkovitost in varnost Zaostanek v rasti pri otrocih
Slide the needle in to pick it up and push the cap completely down over the needle.
Potisnite iglo vanj, da ga boste dvignili, in porinite pokrovček do konca prek igle.
Uncommon: Injection site haemorrhage, injection site atrophy, injection site mass, hypertrophy
Občasni: krvavitev na mestu injiciranja, atrofija na mestu injiciranja, zatrdlina na mestu injiciranja, hipertrofija
Patients with pre-existing hypothyroidism should be treated prior to the start of NutropinAq therapy.
Bolnike s hipotiroidizmom je treba ustrezno zdraviti pred uvedbo zdravljenja z zdravilom NutropinAq.
Talk to you doctor or pharmacist before using NutropinAq.
Pred začetkom uporabe zdravila NutropinAq se posvetujte z zdravnikom ali farmacevtom.
A: Your doctor or nurse will advise you what to do for the last dose in the cartridge.
O: Zdravnik ali medicinska sestra vas bosta seznanila s postopkom za zadnji odmerek iz vložka.
Prepare the injection site by wiping with an antiseptic impregnated swab.
Pripravite mesto injiciranja, tako da ga obrišete z zložencem, prepojenim z antiseptikom.
Up to 0.05 mg/kg bodyweight injected each day under the skin (subcutaneous injection).
Do 0,05 mg/kg telesne mase, ki se ga vsak dan injicira pod kožo (subkutana injekcija).
Q: What should I do if I drop my NutropinAq Pen?
V: Kaj naj storim, če mi injekcijski peresnik NutropinAq Pen pade?
Put a plaster on the injection site if you wish.
Če želite, lahko injekcijsko mesto pokrijete z obližem.
Remove the green pen cap and unscrew the cartridge holder from the pen.
Odstranite zeleni pokrovček injekcijskega peresnika in z injekcijskega peresnika odvijte držalo vložka.
The solution in the cartridge is stable for up to 28 days after first use when stored at 2 - 8°C.
Vsebina vložka je stabilna 28 dni po prvi uporabi, če je vložek shranjen pri temperaturi 2 °C - 8 °C.
NutropinAq is essentially “sodium free”
Zdravilo NutropinAq je v bistvu “brez natrija”.
Uncommon: Abdominal pain, vomiting, nausea, flatulence
Občasni: abdominalna bolečina, bruhanje, navzea, flatulenca
For patients with diabetes mellitus, the dose of insulin may need adjustment after NutropinAq therapy is initiated.
Pri bolnikih s sladkorno boleznijo utegne biti po uvedbi zdravljenja z zdravilom NutropinAq potrebna prilagoditev odmerka insulina.
There have been reports of sleep apnoea and sudden death after initiating therapy with growth hormone in paediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnoea, or unidentified respiratory infection.
Pri pediatričnih bolnikih s Prader-Willijevim sindromom, ki so imeli enega ali več od naslednjih rizičnih dejavnikov: prekomerno telesno maso, anamnezo obstrukcije zgornjih dihalnih poti ali apneje v spanju, ali neprepoznano okužbo dihal, so po uvedbi zdravljenja z rastnim hormonom poročali o pojavu apneje v spanju in nenadne smrti.
Rapid involuntary movements of the eyes (nystagmus), swelling of the optic nerve in the eye (papilloedema), double vision (diplopia), headache, somnolence and vertigo.
Hitri, nehotni gibi očesnih zrkel (nistagmus), oteklina papile vidnega živca (papiledem), dvojni vid (diplopia), glavobol, somnolenca in vrtoglavica.
Rare: Asthenia, face oedema, fatigue, irritability, pain, pyrexia, injection site reaction (haemorrhage, haematoma, atrophy, urticaria, pruritus, swelling, erythema)
Občasni: periferni edem, edem, reakcija na mestu injiciranja (iritacija, bolečina) Redki: astenija, edem obraza, utrujenost, razdražljivost, bolečina, zvišana telesna temperatura, reakcija na mestu injiciranja (krvavitev, hematom, atrofija, urtikarija, srbenje, oteklina, rdečina)
Somatropin is not recommended during pregnancy and should be discontinued if pregnancy occurs.
Somatropina ne uporabljajte med nosečnostjo.
Events of diabetes mellitus and hyperglycaemia were reported in the post-marketing surveillance survey (see section 4.4).
Med spremljanjem zdravila v obdobju trženja so poročali tudi o primerih sladkorne bolezni in hiperglikemije (glejte poglavje 4.4).
In childhood cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropin after their first neoplasm.
Pri osebah, ki so v otroštvu prebolele raka, in so se nato zdravile s somatropinom, so poročali o večjem tveganju, da zbolijo za drugim tumorjem.
A total of 117 patients were treated with somatropin; 36 received somatropin 0.125 mg/kg three times a week and 81 patients received 0.054 mg/kg somatropin daily.
36 bolnic je prejemalo somatropin v odmerku 0,125 mg/kg trikrat na teden, 81 bolnic pa v odmerku 0,054 mg/kg na dan. Zdravljenje je v skupini, ki je somatropin prejemala trikrat na dan, v povprečju trajalo 4,7 let, v skupini, ki je somatropin prejemala dnevno, pa 4,6 let.
NutropinAq is intended for use only with the NutropinAq Pen.
Zdravilo NutropinAq je namenjeno le za uporabo z injekcijskim peresnikom NutropinAq Pen.
NutropinAq 10 mg/2 ml (30 IU) solution for injection.
NutropinAq 10 mg/2 ml (30 i.e.) raztopina za injiciranje
If this appears to be particularly troublesome, you should discuss it with your doctor.
Če ti neželeni učinki postanejo moteči, se posvetujte s svojim zdravnikom.
Physicians and parents should be alert to the development of a limp or complaints of hip or knee pain in patients treated with NutropinAq.
Pri bolnikih, ki se zdravijo z zdravilom NutropinAq, morajo biti zdravniki in starši pozorni na pojav šepanja ali bolečin v kolčnem ali kolenskem sklepu.
The most common adverse events (AEs) observed in the pivotal studies were infection, headache, otitis media, fever, pharyngitis, rhinitis and gastroenteritis and vomiting.
Najpogostejši neželeni učinki v ključnih študijah so bile okužba, glavobol, vnetje srednjega ušesa, zvišana telesna temperatura, faringitis, rinitis, gastroenteritis in bruhanje.
You should consult your doctor regularly as you may need adjustment of your glucocorticoid dose.
Zdravnik bo morda moral prilagoditi odmerek glukokortikoida.
Uncommon: Exfoliative dermatitis, skin atrophy, skin hypertrophy, hirsutism, lipodystrophy, urticaria
Občasni: eksfoliativni dermatitis, atrofija kože, hipertrofija kože, poraščenost moškega tipa pri ženskah, lipodistrofija, urtikarija
Neoplasm
Dojenje
NutropinAq is supplied as a multi-dose solution.
Zdravilo NutropinAq je na voljo v obliki večodmerne raztopine.
Respiratory thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinalnega prostora
• if you have a replacement therapy with glucocorticoids it may reduce the effect of NutropinAq on growth.
Glukokortikoidi lahko zmanjšajo učinek zdravila NutropinAq na rast.